AR020048A1 - Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero. - Google Patents
Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero.Info
- Publication number
- AR020048A1 AR020048A1 ARP980105278A ARP980105278A AR020048A1 AR 020048 A1 AR020048 A1 AR 020048A1 AR P980105278 A ARP980105278 A AR P980105278A AR P980105278 A ARP980105278 A AR P980105278A AR 020048 A1 AR020048 A1 AR 020048A1
- Authority
- AR
- Argentina
- Prior art keywords
- polypeptide
- vitamin
- manufacture
- pharmaceutical composition
- isolated nucleic
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 230000001419 dependent effect Effects 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 title 1
- 229940046010 vitamin k Drugs 0.000 abstract 2
- 229930003448 Vitamin K Natural products 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 235000019168 vitamin K Nutrition 0.000 abstract 1
- 239000011712 vitamin K Substances 0.000 abstract 1
- 150000003721 vitamin K derivatives Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6464—Protein C (3.4.21.69)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/955,636 US6017882A (en) | 1997-10-23 | 1997-10-23 | Modified vitamin K-dependent polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR020048A1 true AR020048A1 (es) | 2002-04-10 |
Family
ID=25497114
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980105278A AR020048A1 (es) | 1997-10-23 | 1998-10-22 | Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero. |
| ARP020101003A AR035786A2 (es) | 1997-10-23 | 2002-03-20 | Variantes de factores de coagulacion dependientes de vitamina k y composiciones que los contienen |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101003A AR035786A2 (es) | 1997-10-23 | 2002-03-20 | Variantes de factores de coagulacion dependientes de vitamina k y composiciones que los contienen |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6017882A (enExample) |
| EP (2) | EP1676919B1 (enExample) |
| JP (1) | JP4276379B2 (enExample) |
| KR (1) | KR20010031370A (enExample) |
| CN (1) | CN1246462C (enExample) |
| AP (1) | AP2000001811A0 (enExample) |
| AR (2) | AR020048A1 (enExample) |
| AT (1) | ATE390486T1 (enExample) |
| AU (1) | AU749279C (enExample) |
| BR (1) | BR9814611A (enExample) |
| CA (1) | CA2307175C (enExample) |
| DE (1) | DE69839313T2 (enExample) |
| DK (1) | DK1090128T3 (enExample) |
| EA (1) | EA200000449A1 (enExample) |
| ES (2) | ES2496104T3 (enExample) |
| HR (1) | HRP20000234A2 (enExample) |
| HU (1) | HU225993B1 (enExample) |
| ID (1) | ID26330A (enExample) |
| IL (1) | IL135603A0 (enExample) |
| IS (1) | IS5449A (enExample) |
| MY (1) | MY136336A (enExample) |
| NO (1) | NO20002025L (enExample) |
| NZ (1) | NZ504114A (enExample) |
| PL (1) | PL194194B1 (enExample) |
| PT (1) | PT1090128E (enExample) |
| SG (1) | SG105547A1 (enExample) |
| TR (1) | TR200001105T2 (enExample) |
| TW (1) | TW587081B (enExample) |
| WO (1) | WO1999020767A1 (enExample) |
| ZA (1) | ZA989597B (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6747003B1 (en) * | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7247708B2 (en) * | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6693075B1 (en) | 1997-10-23 | 2004-02-17 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6998122B1 (en) | 1999-04-30 | 2006-02-14 | Eli Lilly And Company | Protein C derivatives |
| WO2001036462A2 (en) * | 1999-11-19 | 2001-05-25 | Eli Lilly And Company | Protein c derivatives |
| ATE286122T1 (de) | 2000-02-02 | 2005-01-15 | Lilly Co Eli | Protein c derivate |
| JP2003521938A (ja) | 2000-02-11 | 2003-07-22 | イーライ・リリー・アンド・カンパニー | プロテインｃ誘導体 |
| JP2003521930A (ja) * | 2000-02-11 | 2003-07-22 | マキシゲン・エイピーエス | 第ＶＩＩ因子または第ＶＩＩａ因子様分子 |
| US7812132B2 (en) * | 2000-04-28 | 2010-10-12 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7220837B1 (en) | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6423826B1 (en) | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
| US20030211094A1 (en) * | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
| US7160540B2 (en) * | 2000-06-30 | 2007-01-09 | Regents Of The University Of Minnesota | Methods for detecting activity of clottings factors |
| AU7833601A (en) * | 2000-07-31 | 2002-02-13 | Daniel L Sparks | Charged lipid compositions and methods for their use |
| US6933367B2 (en) | 2000-10-18 | 2005-08-23 | Maxygen Aps | Protein C or activated protein C-like molecules |
| EP1370649A1 (en) * | 2001-03-02 | 2003-12-17 | T.A.C. Thrombosis and Coagulation AB | Protein c variants |
| US20050176083A1 (en) * | 2002-03-01 | 2005-08-11 | Bjorn Dahlback | Recombinant protein c variants |
| US20030186862A1 (en) * | 2002-04-02 | 2003-10-02 | Nelsestuen Gary L. | Factor VIIa compositions |
| CN1665925A (zh) * | 2002-04-30 | 2005-09-07 | 马克西根控股公司 | 凝血因子Ⅶ或Ⅶa多肽变体 |
| US20030232075A1 (en) * | 2002-05-06 | 2003-12-18 | University Of Minnesota, A Minnesota Corporation | Compositions for producing factor Xa |
| ES2523655T5 (es) | 2002-06-21 | 2018-04-23 | Novo Nordisk Health Care Ag | Composiciones sólidas estabilizadas de polipéptidos del Factor VIIa |
| US20040176704A1 (en) * | 2003-03-04 | 2004-09-09 | Stevens Timothy A | Collection device adapted to accept cartridge for point of care system |
| EP3103869A1 (en) | 2003-03-18 | 2016-12-14 | Novo Nordisk Health Care AG | Method for the production of factor vii polypeptides |
| AU2004221761B2 (en) | 2003-03-20 | 2010-01-07 | Bayer Healthcare Llc | FVII or FVIIa variants |
| EP1644504B8 (en) | 2003-06-19 | 2010-06-02 | Bayer HealthCare LLC | Factor vii or viia gla domain variants |
| CN1863908B (zh) | 2003-09-09 | 2010-08-04 | 诺和诺德医疗保健公司 | 凝固因子ⅶ多肽 |
| KR100755967B1 (ko) * | 2003-10-23 | 2007-09-06 | 한국타이어 주식회사 | 타이어의 비드와 휠의 갭 측정장치 |
| CN102351953B (zh) | 2003-12-01 | 2017-05-10 | 诺和诺德医疗保健公司 | 液体因子vii组合物的病毒过滤 |
| ATE507822T1 (de) | 2003-12-19 | 2011-05-15 | Novo Nordisk Healthcare Ag | Stabilisierte zusammensetzungen von faktor-vii- polypeptiden |
| ES2642214T3 (es) | 2004-01-21 | 2017-11-15 | Novo Nordisk Health Care Ag | Conjugación de péptidos mediante transglutaminasa |
| EP1831242B1 (en) | 2004-12-23 | 2012-09-26 | Novo Nordisk Health Care AG | Reduction of the content of protein contaminants in compositions comprising a vitamin k-dependent protein of interest |
| US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| EP1893230A2 (en) * | 2005-04-26 | 2008-03-05 | Maxygen Holdings Ltd. | Use of modified factor vii for treating bleeding |
| ES2553160T3 (es) | 2005-06-17 | 2015-12-04 | Novo Nordisk Health Care Ag | Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa |
| EP1904528B1 (en) | 2005-07-13 | 2012-10-31 | Novo Nordisk Health Care AG | Host cell protein knock-out cells for production of therapeutic proteins |
| EP1924689B1 (en) | 2005-09-01 | 2014-08-13 | Novo Nordisk Health Care AG | Hydrophobic interaction chromatography purification of factor vii polypeptides |
| US20090055942A1 (en) | 2005-09-14 | 2009-02-26 | Novo Nordisk Healthcare A/G | Human Coagulation Factor VII Polypeptides |
| JP5570809B2 (ja) | 2006-09-01 | 2014-08-13 | ノボ ノルディスク ヘルス ケア アーゲー | 修飾タンパク質 |
| EP2114379A2 (en) * | 2006-12-20 | 2009-11-11 | Bayer HealthCare LLC | Factor vii and viia compositions |
| UA101155C2 (ru) | 2007-04-13 | 2013-03-11 | Каталист Байосайенс, Инк. | Модифицированный полипептид фактора vii (fvii) и его применение |
| US20080305157A1 (en) * | 2007-06-08 | 2008-12-11 | University Of Maryland Office Of Technology Commercialization | Encapsulation and separation of charged organic solutes inside catanionic vesicles |
| KR101798813B1 (ko) | 2007-12-27 | 2017-11-16 | 박스알타 인코퍼레이티드 | 세포 배양 방법 |
| TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子ｖｉｉ多肽和其用途 |
| DK3266463T3 (da) | 2009-06-09 | 2024-01-08 | Prolong Pharmaceuticals Llc | Hæmoglobinsammensætninger |
| WO2011074578A1 (ja) * | 2009-12-14 | 2011-06-23 | 国立大学法人北海道大学 | 脂質膜構造体に細胞透過能を付与および／または脂質膜構造体の細胞透過能を増強するペプチド、ならびにそれらペプチドと結合した脂質を構成脂質として含む、細胞透過能を有するまたは細胞透過能が増強された脂質膜構造体 |
| TWI595004B (zh) | 2010-11-03 | 2017-08-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
| CN104755492A (zh) | 2012-07-25 | 2015-07-01 | 催化剂生物科学公司 | 修饰的因子x多肽及其应用 |
| US11491212B1 (en) | 2017-09-27 | 2022-11-08 | Catalyst Biosciences, Inc. | Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B |
| CN114728044A (zh) | 2019-08-15 | 2022-07-08 | 介控生化科技公司 | 用于皮下施用和按需求治疗的经修饰的因子vii多肽 |
| WO2021154414A2 (en) | 2020-01-29 | 2021-08-05 | Catalyst Biosciences, Inc. | Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI882746A7 (fi) * | 1987-06-12 | 1988-12-13 | Hoechst Japan | Hybridiproteiini C ja menetelmä sen valmistamiseksi. |
| JPH0246296A (ja) * | 1988-08-09 | 1990-02-15 | Hoechst Japan Ltd | 雑種プロテインｃ及びその製造方法 |
| US5580560A (en) * | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
| JP3330932B2 (ja) * | 1990-01-29 | 2002-10-07 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 抗凝固剤タンパク質 |
| US5504064A (en) * | 1991-04-10 | 1996-04-02 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with an activator of FVII |
-
1997
- 1997-10-23 US US08/955,636 patent/US6017882A/en not_active Expired - Lifetime
-
1998
- 1998-10-20 WO PCT/US1998/022152 patent/WO1999020767A1/en not_active Ceased
- 1998-10-20 HR HR20000234A patent/HRP20000234A2/hr not_active Application Discontinuation
- 1998-10-20 CN CNB988125811A patent/CN1246462C/zh not_active Expired - Fee Related
- 1998-10-20 TR TR2000/01105T patent/TR200001105T2/xx unknown
- 1998-10-20 HU HU0102257A patent/HU225993B1/hu not_active IP Right Cessation
- 1998-10-20 BR BR9814611-4A patent/BR9814611A/pt active Search and Examination
- 1998-10-20 PL PL98340284A patent/PL194194B1/pl unknown
- 1998-10-20 AU AU27024/99A patent/AU749279C/en not_active Ceased
- 1998-10-20 CA CA002307175A patent/CA2307175C/en not_active Expired - Fee Related
- 1998-10-20 ES ES05026205.4T patent/ES2496104T3/es not_active Expired - Lifetime
- 1998-10-20 JP JP2000517087A patent/JP4276379B2/ja not_active Expired - Fee Related
- 1998-10-20 ID IDW20000983A patent/ID26330A/id unknown
- 1998-10-20 AP APAP/P/2000/001811A patent/AP2000001811A0/en unknown
- 1998-10-20 EA EA200000449A patent/EA200000449A1/ru unknown
- 1998-10-20 NZ NZ504114A patent/NZ504114A/xx unknown
- 1998-10-20 IL IL13560398A patent/IL135603A0/xx unknown
- 1998-10-20 KR KR1020007004378A patent/KR20010031370A/ko not_active Ceased
- 1998-10-20 ES ES98967009T patent/ES2303362T3/es not_active Expired - Lifetime
- 1998-10-20 SG SG200203078A patent/SG105547A1/en unknown
- 1998-10-20 DK DK98967009T patent/DK1090128T3/da active
- 1998-10-20 TW TW087117304A patent/TW587081B/zh active
- 1998-10-20 PT PT98967009T patent/PT1090128E/pt unknown
- 1998-10-20 AT AT98967009T patent/ATE390486T1/de active
- 1998-10-20 DE DE69839313T patent/DE69839313T2/de not_active Expired - Lifetime
- 1998-10-20 EP EP05026205.4A patent/EP1676919B1/en not_active Expired - Lifetime
- 1998-10-20 EP EP98967009A patent/EP1090128B1/en not_active Expired - Lifetime
- 1998-10-21 ZA ZA989597A patent/ZA989597B/xx unknown
- 1998-10-22 MY MYPI98004808A patent/MY136336A/en unknown
- 1998-10-22 AR ARP980105278A patent/AR020048A1/es unknown
-
2000
- 2000-04-14 IS IS5449A patent/IS5449A/is unknown
- 2000-04-18 NO NO20002025A patent/NO20002025L/no not_active Application Discontinuation
-
2002
- 2002-03-20 AR ARP020101003A patent/AR035786A2/es active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR020048A1 (es) | Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero. | |
| Lupetti et al. | Candidacidal activities of human lactoferrin peptides derived from the N terminus | |
| ES2056817T3 (es) | Transformacion de trichoderma. | |
| BR9406232A (pt) | Novo agente para controle da atividade celular | |
| ATE408699T1 (de) | Verabreichung von nukleinsäuren und proteinen an zellen | |
| BR9713294A (pt) | "anticorpos contra proteìna relacionada a hormÈnio de paratiróide humano" | |
| AR062867A2 (es) | Proteinas de enlace a interleuquina -18, (il- 18bp), secuencias de adn que codifican para la il -18 bp, secuencias de adnc, un vehiculo de expresion replicable, celula huesped, un proceso para su produccion y aislacion, anticuerpos, composiciones farmaceuticas, el uso de dichas composiciones para la | |
| EP0695171A1 (en) | GONADOTROPINE CONTAINING FREEZER DRIED DROPS | |
| AR004668A1 (es) | Un acido nucleico aislado purificado, un vector de expresion recombinante que lo comprende, una celula que comprende dicho vector, un metodo para laproduccion de un polipeptido de h.pylori, una composicion de vacuna, el uso de dicha composicion para preparar medicamentos, un polipeptido purificado de h. | |
| BRPI9610511B8 (pt) | construções de dna, úteis em terapia genética, compreendendo ao menos uma sequência nucléica de interesse e composição farmacêutica. | |
| ES2077666T3 (es) | Proteina de union a fibronectina y su preparacion. | |
| AR038568A1 (es) | Anticuerpos anti-a beta y su uso | |
| BRPI0113286B8 (pt) | pirazóis substituídos e composição farmacêutica compreendendo os mesmos. | |
| BR0316435A (pt) | Produtos genéticos expressos diferencialmente em tumores e uso dos mesmos | |
| BRPI0417684A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| ATE415480T1 (de) | B7l-1 moleküle | |
| NO20052363L (no) | Interferon-alfa polypeptider og konjugater | |
| ES2173471T3 (es) | Analisis para homocisteina y homocisteina desulfurasa a partir de tricomonas viginalis de protozoos. | |
| Yoshikawa et al. | G protein β5 subunit interactions with α subunits and effectors | |
| WO2001012661A3 (en) | RECEPTOR-MEDIATED UPTAKE OF AN EXTRACELLULAR BCL-xL FUSION PROTEIN INHIBITS APOPTOSIS | |
| AR023699A1 (es) | Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica | |
| CO5170467A1 (es) | Capsulas de eter de celulosa libres de turbiedad y proceso para hacer las mismas | |
| ATE397662T1 (de) | Neues polypeptid, dafür kodierende dna und deren verwendungen | |
| BRPI0406668A (pt) | Recipiente de segurança, processo para a produção do mesmo, e, uso de um meio que contém pelo menos um polìmero | |
| ES2052513T3 (es) | Nuevos polipeptidos, su fabricacion y empleo. |